Combined Efficacy of CXCL5, STC2, and CHI3L1 in the Diagnosis of Colorectal Cancer

Table 2

Results for indicated biomarkers in the diagnosis of early CRC from the non-CRC controls.

	Training set (n = 467, 116 CRCs vs. 351 controls)				Testing set (n = 186,42 CRCs vs. 144 controls)
	AUC (95% CI)	Sensitivity	Specificity	Accuracy	AUC (95% CI)	Sensitivity	Specificity	Accuracy
CEA	0.724 (0.681–0.764)	0.431	0.869	0.780	0.810 (0.747–0.864)	0.476	0.909	0.715
CA199	0.677 (0.633–0.720)	0.353	0.798	0.687	0.577 (0.503–0.649)	0.357	0.819	0.715
Model_1	0.767 (0.726–0.805)	0.491	0.863	0.771	0.817 (0.754–0.870)	0.476	0.889	0.796
CXCL5	0.851 (0.815–0.892)	0.776	0.868	0.845	0.812 (0.749–0.866)	0.667	0.861	0.817
STC2	0.815 (0.776–0.849)	0.767	0.849	0.829	0.870 (0.812–0.914)	0.952	0.799	0.833
CHI3L1	0.790 (0.750–0.826)	0.647	0.809	0.769	0.738 (0.669–0.800)	0.476	0.840	0.758
Model_2	0.925 (0.897–0.947)	0.793	0.917	0.886	0.926 (0.979–0.959)	0.786	0.931	0.898

Early CRC was defined as stage 0 and Ι.